Clinical Trial Update: Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of a quadrivalent HPV vaccine in healthy Chinese females aged 9 to 19; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer Stage Iia
• Cervical Intraepithelial Neoplasia 1
• Cervical Intraepithelial Neoplasia 2
• Cervical Intraepithelial Neoplasia 3
• Genital Warts
• Human Papillomavirus Infection

Drugs mentioned

• quadrivalent HPV vaccine

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Status: RECRUITING